Some day I'll learn to buy the shares of the med-tech stocks I really
like before I write them up for Seeking Alpha. Emerging eye care
diagnostic company TearLab (TEAR)
was already on its way up when I wrote on the company in March of this
year, but the stock has gone on for a further gain of about 66% since
then, and it's hard to beat that sort of performance.
In the
meantime, nothing has changed to dull my enthusiasm for the stock other
than to say that the sharp move up has blunted some of the long-term
potential from here. TearLab continues to book orders literally faster
than they can fulfill them, and the margin leverage is coming along
nicely. Now with the possible entry of generic competitors to Allergan's (AGN)
Restasis - the one prescription pharmaceutical for the condition
TearLab diagnoses - the value of an accurate diagnostic to eye care
professionals could be all the greater.
Please read the full article here:
The Only Tears From TearLab Are Tears Of Joy For Now
No comments:
Post a Comment